Clonazepam — Klonopin — is the long-acting BZD that addresses many of alprazolam's problems while preserving the panic and anxiety effect. The half-life is approximately 30 hours, more than double alprazolam's. The clinical consequences of that longer tail shape clonazepam's role in modern practice.
- Class
- Long-acting benzodiazepine
- Mechanism
- GABA-A positive allosteric modulator
- Typical dose
- 0.5-4 mg/day in 1-2 divided doses
- Half-life
- ~30 hours
- FDA indications
- Panic disorder, seizure disorders, REM sleep behavior disorder (off-label)
- Key adverse effects
- Sedation, cognitive impairment, ataxia, tolerance, dependence, withdrawal (less severe than alprazolam due to longer half-life)
Black box: Concomitant opioid use; abuse potential and dependence
Often preferred over alprazolam for chronic anxiety/panic — longer half-life means smoother coverage, less rebound, easier taper. Effective for REM sleep behavior disorder (vivid dream enactment). Once-daily or twice-daily dosing improves adherence.
Smoother coverage. With clonazepam at BID dosing, the plasma level stays in the therapeutic range without significant inter-dose dropping. Patients don't experience the rebound anxiety that alprazolam produces. Tolerance develops more slowly.
Clonazepam is a long-acting, high-potency benzodiazepine whose extended half-life makes it the smoothest of the class for sustained coverage.
Mechanism note: Clonazepam's long half-life smooths coverage and tapers but causes accumulation — a benefit for stability, a liability for cumulative sedation and falls in older patients.
Less severe withdrawal. The long half-life means withdrawal symptoms emerge gradually rather than sharply when doses are missed or tapered. The taper can proceed more smoothly. Patients sometimes use clonazepam as the bridge for tapering off alprazolam — converting first, then tapering the longer-acting agent.
Lower abuse liability than alprazolam. Slower onset and longer duration reduce the reinforcement profile. Clonazepam is still controlled (Schedule IV), still has abuse potential, still should be prescribed thoughtfully — but it's a more manageable agent for chronic use than alprazolam.
One specific indication where clonazepam is first-line: REM sleep behavior disorder. The patient who acts out dreams — kicking, punching, vocalizing during REM sleep — is often having their first manifestation of a synucleinopathy (Parkinson's, Lewy body dementia) years before motor symptoms appear. Clonazepam 0.25-2 mg at bedtime is highly effective. Melatonin is the alternative or adjunct.
For chronic anxiety, panic, or seizure disorders, clonazepam is generally a better long-term BZD choice than alprazolam. The decision to use any BZD long-term remains complicated by the tolerance, dependence, and fall risk concerns — but if a BZD is being chosen, clonazepam's profile is usually the safer one.